Actual results may differ materially, and we disclaim any obligation to update any forward-looking statements or outlook. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release. We have three updates today: our financials, network growth, and AI products. We delivered $169 million in revenue for the second quarter of our fiscal 2026, which represents 23% year-on-year growth and a 7% beat from the high end of our guidance range.
Our bottom line was also strong in Q2, with an Adjusted EBITDA margin of 60%, or $101 million, which was 15% above the high end of our guidance. Our Adjusted EBITDA grew 32% year-on-year, while our free cash flow was up 37% year-on-year. Okay, turning now to our network growth and engagement, which reached new highs in Q2. Our Newsfeed led the way with an all-time record number of quarterly active subscribers and double-digit growth in the number of articles read or tapped.
Our AI tools once again grew the fastest, with quarterly active prescribers up more than 50% from the prior quarter. Okay, now for an update on our Pathway acquisition and AI Scribe growth. Just seven weeks after announcing our acquisition, we fully integrated Pathway's entire medical data set and AI models into DoxGPT, now live across both our web and mobile apps. We're also the first medical AI to provide direct full-text PDF access to over 2,000 medical journals, including all the top titles, through a unique referral with Research Solutions software.